Paradigm Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.31%

Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Paradigm Biopharmaceuticals Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$71.83K
≈ $50.82K USD Cash + Short-term Investments

Total Assets

AU$23.15 Million
≈ $16.38 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Paradigm Biopharmaceuticals Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Paradigm Biopharmaceuticals Ltd (PAR) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$71.83K 0.31%
Total Liquid Assets AU$71.83K 0.31%

Asset Resilience Insights

  • Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.31% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Paradigm Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.00% AU$0.00
≈ $0.00
AU$24.57 Million
≈ $17.39 Million
--
2024-06-30 0.17% AU$46.20K
≈ $32.69K
AU$27.39 Million
≈ $19.38 Million
+0.10pp
2023-06-30 0.07% AU$46.20K
≈ $32.69K
AU$67.07 Million
≈ $47.46 Million
-0.02pp
2022-06-30 0.09% AU$46.20K
≈ $32.69K
AU$50.69 Million
≈ $35.87 Million
+0.04pp
2021-06-30 0.05% AU$46.20K
≈ $32.69K
AU$84.79 Million
≈ $60.00 Million
-0.61pp
2020-06-30 0.66% AU$746.20K
≈ $527.98K
AU$112.36 Million
≈ $79.50 Million
-6.94pp
2019-06-30 7.60% AU$6.50 Million
≈ $4.60 Million
AU$85.51 Million
≈ $60.50 Million
--
2017-06-30 0.00% AU$0.00
≈ $0.00
AU$14.35 Million
≈ $10.15 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$12.35 Million
≈ $8.74 Million
--
pp = percentage points

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology
Market Cap
$63.20 Million
AU$89.33 Million AUD
Market Cap Rank
#21034 Global
#717 in Australia
Share Price
AU$0.17
Change (1 day)
-5.56%
52-Week Range
AU$0.14 - AU$0.47
All Time High
AU$4.35
About

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more